Amarin Corp Plc (AMRN)

[Birdbrain Ideas]

Oh boy. I wouldn't get your hopes up. Amarin has submitted all of its written arguments to the Federal Circuit already. And so has Hikma. At best, the appeals panel can return the case to the lower court to restart all the discovery and motions that would ensue over the next year before the trial judge has the option of rejecting Amarin's claims all over again. It would be great for the appeals court to revive the lawsuit because it would put Amarin in a better position to negotiate a settlement with Hikma. And it might scare some other generics into being very careful in their sales of a drug that probably makes them little money anyway.

But there won't be any surprises or new information about the case forthcoming at this week's earnings call, and a revival of the case by the Federal Circuit would be unlikely to have much effect, if any, on Amarin's share price.